Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 May;61(5):725-36.
doi: 10.1111/j.1742-1241.2007.01338.x. Epub 2007 Mar 16.

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

P Kuna  1 , M J Peters, A I Manjra, C Jorup, I P Naya, N E Martínez-Jimenez, R Buhl
Affiliations
Randomized Controlled Trial

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

P Kuna et al. Int J Clin Pract. 2007 May.

Abstract

This randomised, double-blind, 6-month study compared budesonide/formoterol for maintenance and relief with salmeterol/fluticasone and a fixed maintenance dose of budesonide/formoterol, both with terbutaline for relief. Following a 2-week run-in, 3335 symptomatic adults and adolescents (mean FEV1 73% predicted, mean inhaled corticosteroid dose 745 microg/day) received budesonide/formoterol 160/4.5 microg one inhalation bid plus additional inhalations as needed, salmeterol/fluticasone 25/125 microg two inhalations bid plus as-needed terbutaline or budesonide/formoterol 320/9 microg one inhalation bid plus as-needed terbutaline. Budesonide/formoterol for maintenance and relief prolonged the time to first severe exacerbation requiring hospitalisation, emergency room treatment or oral steroids (primary variable) vs. fixed-dose salmeterol/fluticasone and budesonide/formoterol (p=0.0034 and p=0.023 respectively; log-rank test). Exacerbation rates were 19, 16 and 12 events/100 patients/6 months for salmeterol/fluticasone, fixed-dose budesonide/formoterol and budesonide/formoterol for maintenance and relief, respectively, [rate reduction vs. fixed-dose salmeterol/fluticasone (0.61; 95% CI 0.49-0.76, p<0.001) and vs. fixed-dose budesonide/formoterol (0.72; 95% CI 0.57-0.90, p=0.0048)]. Budesonide/formoterol maintenance and relief patients used less inhaled corticosteroid vs. salmeterol/fluticasone and fixed-dose budesonide/formoterol patients. All treatments provided similar marked improvements in lung function, asthma control days and asthma-related quality of life. Budesonide/formoterol for maintenance and relief reduces asthma exacerbations and maintains similar daily asthma control at a lower overall drug load compared with fixed-dose salmeterol/fluticasone and budesonide/formoterol.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient flow. bid, twice daily; ICS, inhaled corticosteroid; SMART, Symbicort® maintenance and reliever therapy. Terbutaline dose expressed as 0.5 mg/inhalation metered dose corresponds to 0.4 mg/inhalation delivered dose
Figure 2
Figure 2
Time to first severe exacerbation (deterioration in asthma resulting in hospitalisation/emergency room treatment, or the need for oral steroids for ≥ 3 days). SMART, Symbicort® (budesonide/formoterol) maintenance and reliever therapy
Figure 3
Figure 3
Cumulative rate of (A) severe exacerbations and (B) hospitalisations/emergency room treatments caused by asthma; p-values are derived from relative rate analysis (Poisson regression analysis). SMART, Symbicort® (budesonide/formoterol) maintenance and reliever therapy
Figure 4
Figure 4
Mean overall (A) Asthma Quality of Life Questionnaire (standardised version) [AQLQ(S)] and (B) Asthma Control Questionnaire (ACQ) scores over the duration of the study. QoL, quality of life; SMART, Symbicort® (budesonide/formoterol) maintenance and reliever therapy
Figure 5
Figure 5
Range of daily mean doses of ICS/LABA reported by individual study patients. *Mean ICS doses converted to BDP equivalents based on GINA (13) guidelines. Compared with fixed-dose budesonide/formoterol treatment, 9 : 1 (ratio: 63% divided by 7%) SMART-treated patients reduced their mean daily dose by at least 160/4.5 μg than increased their dose by at least 160/4.5 μg. SMART, Symbicort® (budesonide/formoterol) maintenance and reliever therapy; BDP, beclomethasone dipropionate
See this image and copyright information in PMC

References

    1. Aalbers R, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin. 2004;20:225–40. - PubMed
    1. Lalloo UG, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest. 2003;123:1480–7. - PubMed
    1. Shapiro G, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med. 2000;161:527–34. - PubMed
    1. Rabe KF, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114:40–7. - PubMed
    1. Partridge MR, et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. - PMC - PubMed

Publication types